The pill US drug companies dare not market

Article Abstract:

Drug companies such as American Home Products Corp. and Schering AG have developed FDA-approved morning-after emergency contraceptive pills for women, but they refuse to market the controversial drugs due to risk of litigation, uncertain profits, and abortion politics. Gynetics Inc. (Belle Meade, NJ) expects to soon gain FDA approval and large profits for its own emergency contraceptive pill. Medical analysts predict that the morning-after pill market could reach annual sales of $300 million, with a possible annual demand of up to 9 million prescriptions, while reducing by half the country's annual 3 million unwanted pregnancies.

Comment:

Has developed new morning-after emergency contraceptive pill but refuses to market it in the US

Germany, Company Planning/Goals, Fertility Preparations, Schering AG, Fertility agents, Wyeth

---

Immunex says chemotherapy drug benefited multiple-sclerosis patients

Article Abstract:

The chemotherapy drug, Novantrone, has proved to help in the treatment of multiple sclerosis patients, according to pharmaceutical manufacturer Immunex Corp. The company plans to announce the results of a late-stage clinical trial at an upcoming scientific conference in Sweden. Immunex, which already has FDA approval for Novantrone in the treatment of prostrate cancer and leukemia, owns the North American marketing rights for the drug. American Home Products Corp. owns overseas rights for Novantrone.

Comment:

Has announced that the chemotherapy drug, Novantrone, has proved to help in the treatment of multiple sclerosis patients

New Products/Services, Immunex Corp.

---

EntreMed reverses midweek stock loss as NCI verifies an anti-tumor agent

Article Abstract:

EntreMed Inc. may have lost its partner Bristol-Myers Squibb in the search and research of anti-tumor drugs, but it will continue the pursuit anyway. The research will be continued by the National Cancer Institute with the hopes of bringing both angiostatin and endostatin to the point where they can be used in human trials by year's end. Thus far, the two have been shown to halt the growth of cancerous tumors in mice only and by one researcher only, Dr. Jonah Folkman.

Comment:

Company will continue its work on drugs without the help of Bristol-Myers

Science & research, Pharmaceutical preparations, Research, Pharmaceutical industry, Abstract, EntreMed Inc., ENMD, United States. National Cancer Institute

Similar abstracts:

• Abstracts: Roche recalls drug to reduce blood pressure. Novartis changes gene-therapy-management strategy. Ciba chairman injects a dose of U.S. style
• Abstracts: New profits in old bottles; companies find bonus in drugs that cure several ills. SmithKline to sell off units for $1.97 billion
• Abstracts: GM strike spreads to communities far from Flint factories. General Motors and U.A.W. agree on end to strike
• Abstracts: Breaking the publishing mold; a new book empire your mother would love. part 2 2 book giants in global deal to sell titles via Internet
• Abstracts: G.M. dealers see dwindling supply of hot models. Powerboats, picket lines: strikers are getting by: at G.M. life styles worth defending

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.